Radius Residential Care (NZSE:RAD) Research & Development: NZ$0.0 Mil (TTM As of Mar. 2026)


NZSE:RAD Radius Residential Care Ltd NZSE:RAD
40 GF Score
Price NZ$0.39
GF Value NZ$0.29
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Radius Residential Care Research & Development?

Radius Residential Care NZSE:RAD 40 Research & Development is NZ$0.0 Mil as of Mar. 2026. GuruFocus rates NZSE:RAD with a GF Score™ of 40/100 and a GF Value™ of NZ$0.29 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Radius Residential Care's Research & Development for the six months ended in Mar. 2026 was NZ$0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was NZ$0.0 Mil.

Radius Residential Care  (NZSE:RAD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Radius Residential Care Research & Development Related Terms

Radius Residential Care Research & Development Historical Data

* Premium members only.

The historical data trend for Radius Residential Care's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radius Residential Care Research & Development Chart

Radius Residential Care Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Radius Residential Care Semi-Annual Data
Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NZSE:RAD
40GF Score
Radius Residential Care Ltd NZSE:RAD
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Radius Residential Care Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NZ$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NZ$0.0 Mil mean?
Radius Residential Care (NZSE:RAD) has a Research & Development of NZ$0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Radius Residential Care and its competitors.
Is Radius Residential Care's Research & Development too high?
Radius Residential Care's current Research & Development is NZ$0.0 Mil. Overall, Radius Residential Care has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Radius Residential Care's Research & Development compare to HCA and THC?
Radius Residential Care's Research & Development of NZ$0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Radius Residential Care and its competitors. Radius Residential Care's current Research & Development is NZ$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radius Residential Care stock overvalued right now?
Based on GuruFocus' analysis, Radius Residential Care (NZSE:RAD) is currently considered Significantly Overvalued. The stock's GF Value™ is NZ$0.29, compared to a current price of NZ$0.39 — trading 32.8% above its estimated fair value. The current Research & Development is NZ$0.0 Mil. Radius Residential Care's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Radius Residential Care (NZSE:RAD), the current Research & Development is NZ$0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Radius Residential Care (NZSE:RAD) Overvalued in 2026?

Based on GuruFocus' analysis, Radius Residential Care stock appears to be overvalued. The current stock price of NZ$0.39 is trading 32.8% above its estimated GF Value™ of NZ$0.29. GuruFocus considers Radius Residential Care to be Significantly Overvalued.

Key valuation signals for NZSE:RAD:

  • Research & Development: NZ$0.0 Mil
  • GF Value™: NZ$0.29 vs. price of NZ$0.39 (32.8% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the NZSE:RAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Radius Residential Care Business Description

Address 56 Parnell Road, Level 4, Parnell, Auckland, NTL, NZL, 1052
Radius Residential Care Ltd is a health and aged care provider for elderly and disabled people. The company provides residential care, hospital care, dementia care, respite care, and palliative care. Additionally, the company offers Young Disabled Care services for those under 65 who require assistance with self-care, mobility, and/or communication. It has one operating segment, being the provision of aged care in New Zealand.
40GF Score

Get the complete analysis for NZSE:RAD

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NZ$0.39
Price
NZ$0.29
GF Value